Johnson & Johnson Family of Companies
NEWS
The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
The Janssen Pharmaceutical Companies, part of Johnson & Johnson, presented two-year data from its IM-UNITI trial of Stelara (ustekinumab) in Crohn’s disease.
The Janssen Pharmaceutical Companies, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray.
Genmab A/S, and Johnson & Johnson’s Janssen division have pulled the plug on the Phase Ib/II trial of daratumumab in combination with Roche’s Tecentriq.
A Los Angeles jury sided with 68-year-old Joanne Anderson, who was diagnosed with mesothelioma allegedly linked to a Johnson & Johnson talc product. It is the second similar award regarding the product.
Sun Pharma received approval from the U.S. Food and Drug Administration (FDA) for Yonsa (abiraterone acetate) to treat metastatic castration-resistant prostate cancer (mCRPC). Sun will launch the drug in the U.S. via a licensing deal with Churchill Pharmaceuticals, the original developer of the drug.
Johnson & Johnson’s Janssen division has decided to end its trials of atabacestat, a BACE inhibitor, for Alzheimer’s disease.
On May 19 every year the people who are afflicted with IBD disorders unite across the globe to raise awareness of the disease and urge governments and healthcare systems to continue to focus on the development of necessary treatments.
JOBS
IN THE PRESS